Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Minna TaskinenSirpa Leppä

Abstract

Tumour-infiltrating mast cells (MCs) can remodel tumour microenvironment and growth by suppressing immune responses and potentiating angiogenesis. Furthermore, accumulation of MCs in follicular lymphoma (FL) correlates with unfavourable prognosis after immunochemotherapy. Here we investigated whether tumour vascularity is associated with MC content and outcome in FL patients treated with immunochemotherapy. Microvessel density (MVD) and MC content were determined immunohistochemically from pretreatment samples of 95 FL patients using CD31, CD34 and mast cell tryptase antibodies. Gene expression data from a separate set of 24 FL patients were analysed for comparison. All patients were treated with the combination of rituximab (R) and cyclophoshamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy. Increased CD31+ MVD correlated positively with the number of tumour infiltrating MCs and CD34+ vessels, and negatively with the outcome. Overall survival and progression-free survival were significantly better among patients with low CD31+ MVDs. In multivariate analyses, CD31+ MVD had prognostic value independently of Follicular Lymphoma Prognostic Index but not of MC content. Consistent with the immunohistochemical data, high C...Continue Reading

References

Jun 5, 2003·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Klas Norrby, Börje Ridell
May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Nov 19, 2004·The New England Journal of Medicine·Sandeep S DaveLouis M Staudt
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daphne de Jong
Mar 8, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexandra M LevineParkash S Gill
Oct 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Abigail M LeeLindsey K Goff
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomás AlvaroLluis E Pons
Oct 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Minna TaskinenSirpa Leppä
Jul 18, 2008·Nature Reviews. Cancer·Craig MurdochClaire E Lewis
Feb 24, 2009·Biochimica Et Biophysica Acta·Steven MaltbyKelly M McNagny

❮ Previous
Next ❯

Citations

Jun 11, 2011·Best Practice & Research. Clinical Haematology·E LeichA Rosenwald
Apr 2, 2016·Critical Reviews in Oncology/hematology·Domenico Ribatti
May 12, 2012·Toxicon : Official Journal of the International Society on Toxinology·C C DrewesS H P Farsky
May 7, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alba Matas-CéspedesPatricia Pérez-Galán

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.